Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55.6M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
61M
-
Shares change
-
-4.74M
-
Total reported value, excl. options
-
$6.53B
-
Value change
-
-$599M
-
Put/Call ratio
-
0.19
-
Number of buys
-
68
-
Number of sells
-
-93
-
Price
-
$107.22
Significant Holders of Ascendis Pharma A/S - ADR (ASND) as of Q1 2023
209 filings reported holding ASND - Ascendis Pharma A/S - ADR as of Q1 2023.
Ascendis Pharma A/S - ADR (ASND) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (6.96M shares), Artisan Partners Limited Partnership (6.84M shares), FMR LLC (5.15M shares), JANUS HENDERSON GROUP PLC (3.53M shares), T. Rowe Price Investment Management, Inc. (3.47M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.37M shares), Avoro Capital Advisors LLC (3.33M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (3.15M shares), WELLINGTON MANAGEMENT GROUP LLP (2.93M shares), and GOLDMAN SACHS GROUP INC (2.55M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.